TIGO

TIGO GmbH, a company registered under German law, is a biotech company with a unique and patented technology platform in the field of recombinant receptor antagonists and other modulators to the cytokine interferon gamma (IFN-y), e.g. interferon beta (IFN-ß)... TIGO´s unique approach is to develop such modulators as well as its proprietary innovative antagonists of IFN-y, targeted to counteract the negative effects of IFN-y in alopecia areata (patchy hair loss). Alopecia areata is widely regarded as being a tissue specific autoimmune disease caused by IFN-y. There is a high unmet need for causal therapies as the currently available therapeutical approaches are disappointing and do only reveal limited success.

Also known as: TIGO GmbH

Registration numbers: HRB 22810 (W)

VAT numbers: DE 253791418

Primary location: Wiesbaden Germany